US FDA Approves Bladder Cancer Drug
|04/13/2019||Posted by BusinessMediaguide.Com under General World News||
Johnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration
The list price of the drug, known chemically as erdafitinib, will range between $10,080 and $22,680 for a 28-day supply, depending on the dosage, J&J said.
Balversa is the first approved drug in a class known as FGFR inhibitors that targets growth factor receptors involved in cell growth and division.
The drug is approved for use in patients whose cancer has progressed during or after chemotherapy and have specific genetic alterations known as FGFR3 or FGFR2. Patients read more >>>